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Progesterone and corticotropin-releasing hormone (CRH) have a critical role in pregnancy and labor, as changes related to these
hormones are crucial for the transition from myometrial quiescence to contractility. The mechanisms related to their eﬀect
diﬀer between humans and other species, thus, despite extensive research, many questions remain to be answered regarding
their mediation in human labor. Immune responses to progesterone and CRH are important for labor. Progesterone acts as an
immunomodulator which controls many immune actions during pregnancy, and its withdrawal releases the inhibitory action
on inﬂammatory pathways. In humans, a “functional” progesterone withdrawal occurs with onset of labor through changes in
progesterone metabolism, progesterone receptors, and other molecules that either facilitate or antagonize progesterone function.
Placental CRH acts on the fetal pituitary-adrenal axis to stimulate adrenal production of androgens and cortisol and also
acts directly on myometrial cells via its receptors. CRH also aﬀects inﬂammatory signals and vice versa. Interactions between
progesterone and CRH additionally occur during labor. We describe the role of these two hormones in human myometrium and
their interactions with the immune system during labor.
1.Introduction
Mechanical and endocrine mechanisms, immune system
responses with inﬂammatory signals, and release of cy-
tokines, prostaglandins, and oxytocin contribute among
others to the transition from myometrial quiescence to labor
initiation. The role of these agents has been extensively stud-
ied in many animal models, although diﬀerences exist be-
tween species, and therefore these observations do not
always apply to humans [1]. Progesterone and corticotropin-
releasing hormone (CRH) are both among the most impor-
tant mediators of labor. Their role has been studied in many
diﬀerent tissues and organs during pregnancy and labor [2].
Progesterone withdrawal occurs towards the onset of labor
through many mechanisms. Placental CRH acts on the fetal
pituitary-adrenal axis and directly on myometrial cells to
facilitate labor.
Apart from changes in the endocrine milieu, immune
system responses are also vital for labor. During the onset
of labor immune cells such as neutrophils, macrophages and
T cells invade into cell membranes, decidua, cervix, and my-
ometrium as they are attracted by local chemokines [3, 4].
Characterization of the human myometrial transcriptome
andcomprehensionofthechangesingeneexpressionduring
spontaneous labor at term have considerably elucidated the
association between spontaneous labor and biological pro-
cesses such as inﬂammatory response, chemotaxis, and
immune response, as well as molecular functions like cy-
tokine and chemokine activity and chemokine receptor
binding. Among the overexpressed genes were interleukin2 Clinical and Developmental Immunology
8 (Il-8), Il-6, monocyte chemotactic protein-1 (MCP-1),
leukocyte immunoglobulin-like receptor, subfamily A mem-
ber 5 (LILRA5), chemokine C-C motif ligand 6 (CXCL6),
nuclear factor of kappa-light chain gene enhancer in B-cells
inhibitor zeta (NFKBIZ), and suppressor of cytokine signal-
ing 3 (SOCS3). Software for pathway analysis of microar-
rays and gene expression data revealed that the pathways
involved in inﬂammatory response were enriched during
spontaneous labor at term [5].
The increased expression of cytokines in the my-
ometriumresultsinincreasedcontractility.Proinﬂammatory
cytokines contribute to the onset of labor irrespectively
of the presence of inﬂammation. Interleukin 1-β (IL-1β),
IL-6, and IL-8 trigger the transcription of genes through
activation of nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) [6]. IL-6 is considered to be
mainly a proinﬂammatory cytokine [7, 8], but may possibly
also have anti-inﬂammatory properties and its upregulation
in parallel with IL-1β and tumor necrosis factor-alpha
(TNF-α) may contribute to a balance between pro- and
anti-inﬂammatory cytokines [9]. Lipoxin A4 is an anti-
inﬂammatory compound that may moderate inﬂammatory
response and modulate inﬂammatory events taking place
in the myometrium during parturition [10]. During labor,
myometrial cells are connected by gap junctions that are
created by multimers of connexin 43 for the achievement
of coordinated and synchronous myometrial contractions,
while progestins repress connexin 43 gene expression in
myometrial cells [11–13]. Moreover, oxytocin receptors
(OTRs) in myometrium increase during labor, and oxytocin
promotes myometrial contractility by increasing the intra-
cellular Ca2+ ions and the production of prostaglandins [14–
16]. In uterine tissues proinﬂammatory cytokines such as IL-
1β and TNF increase cyclooxygenase-2 (COX-2) expression,
OTRs, Prostaglandin H Synthase type 2 (PGHS-2), and
connexin-43 [6]. In this study we review some of the
most recent advances in scientiﬁc knowledge concerning
progesterone and CRH function and interactions in human
labor, placing particular focus on the eﬀect on myometrial
cells. We also discuss the immune system responses to these
hormones.
2.ProgesteroneWithdrawalinLabor
According to the “progesterone block” hypothesis, pro-
posed by Arpad Csapo, progesterone blocks myometrial
contraction and maintains pregnancy, while its withdrawal
transforms the myometrium to the laboring state [17]. In
rats and other animals the initiation of labor coincides with
a decline in progesterone serum concentration. However,
in humans progesterone levels remain high throughout
pregnancy and during labor [1]. This has led to the hypoth-
esis of a “functional” progesterone withdrawal that may
occurthroughmechanismssuchasprogesteronemetabolism
into inactive forms, expression of diﬀerent progesterone
receptor isoforms, altered expression of molecules that act
as progesterone coregulators, and ﬁnally the antagonism of
NF-κB[ 18]w i t hp r o g e s t e r o n e( Figure 1).
2.1. Progesterone Metabolism. In mice, the catabolism of
progesterone to the inactive C21-steroid 5α dihydropro-
gesterone by the enzyme steroid 5α-reductase facilitates
cervical ripening, while mice deﬁcient in this enzyme fail
to deliver at term despite normal uterine contractions and
progesterone withdrawal in blood [19]. In mice with a tar-
geteddisruptionof20α-hydroxysteroiddehydrogenase(20α-
HSD) gene (which converts progesterone to the biologically
inactive metabolite 20α-dihydroprogesterone), the mean
duration of pregnancy is signiﬁcantly prolonged compared
to the controls [20]. In cultured rat ovarian granulose
cells IL-1β stimulates 20α-hydroxysteroid dehydrogenase
activity [21]; however it is unknown if such an eﬀect may
also take place in myometrium during labor. In humans,
experiments with endocervical cells of women in labor
show that, during cervical ripening and parturition, 17β-
hydproxysteroid dehydrogenase type 2 activity decreases,
resulting in increased 20α-hydroxyprogesterone and estra-
diol levels because of decreased conversion of 20α hydrox-
yrogesterone to progesterone and decreased conversion of
estradiol to estrone. These changes result in inactivation of
progesterone responses [22].
2.2. Altered Expression of Progesterone Receptors. The role
of progesterone receptors in human pregnancy has been
recently extensively reviewed [23]. In humans, there are two
major isoforms of progesterone receptor, PR-A and PR-B,
which belong to the nuclear receptor superfamily, as well as
many other isoforms which have so far given evidence of
being less signiﬁcant. The expression of the various isoforms
may contribute to the functional withdrawal of progesterone
during labor. In human myometrial cells, the ratio of PR-
A:PR-BmRNAincreases2-to3-foldcomparedwiththenon-
laboring state, mainly due to overexpression of PR-A. This
change induces a “functional estrogen activation” through
increased estrogen receptor α (ERα) expression [24]. PR-A
may also suppress the transcriptional activity of PR-B, which
is the main receptor for the nuclear signal transduction of
progesterone [25, 26]. Apart from myometrial contractions,
the functional progesterone withdrawal due to the altered
expression of PR-A, PR-B isoforms may also contribute to
the cervical changes during labor [27, 28].
The binding of progesterone to PR-C, which is a soluble
form of the receptor, may sequester available progesterone
away from PR-B and thereby diminish its biological eﬀect
[18].Inanotherstudyofwomeninlabor,PR-Cproteinlevels
were increased in cytoplasmic fractions of fundal myome-
trial cells, but not in cells of the lower uterine segment,
while PR-B protein levels increased only in the laboring
fundal endometrium. In the same study PR-A could not
be detected despite the presence of PR-A mRNA. This
paradoxical increase in PR-B protein may be the result of the
associated reduced progesterone activity. In human telom-
erase reverse transcriptase- (hTERT-) immortalized human
myometrial cells, PR-C compromises PR-B transactivation.
The upregulation of PR-B and PR-C expression was asso-
ciated with activation of NF-κB, while upregulation of NF-
κB was observed in pregnant mouse uterus, coinciding withClinical and Developmental Immunology 3
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Figure 1: Mechanisms of functional progesterone withdrawal for the initiation of parturition. Progesterone binds to its nuclear receptor PR
and activates genomic pathways that maintain uterine quiescence. Functional progesterone withdrawal occurs through many mechanisms:
(a) the expression of diﬀerent PR isoforms (increased PR-A:PR-B ratio and the expression of PR-C), (b) the decreased expression of
PR coactivators, such as CBP, SRC-2, SRC-3, (c) binding of progesterone to membrane progesterone receptors (mPR) which activate
nongenomic pathways, and (d) immune factors such as cytokines and chemokines activating NF-κB, that in turn lead to functional
progesterone withdrawal. NF-κB increases the expression of COX-2 and contractile genes. Progesterone withdrawal together with increased
expression of COX-2 and contractile genes results in increased myometrial contractions, which is a vital component for the initiation of
labor. PR: progesterone receptor, CBP: CREB-binding protein, SRC: steroid receptor coactivators, NF-κB: nuclear factor kappa-light-chain
enhancer of activated B cells, mPRs: membrane progesterone receptors, COX-2: cyclooxygenase-2.
PR isoform expression. In addition, treatment of myometrial
cells with the cytokine IL-1β further induces NF-κBa c t i -
vation and concomitant increase in PR expression, which
suggests that labor-associated changes in myometrium are
associated with uterine inﬂammatory pathways [29].
A number of other progesterone receptors (mPR-α,
mPR-β,a n dm P R - γ ) have been identiﬁed which are believed
to be structurally related to the G-protein complex. mPR-α
and mPR-β receptors were found to be expressed in human
pregnant myometrial cells, and progesterone activation of
these receptors may induce nongenomic actions, resulting
in inhibition of adenyl cyclase, phosphorylation of myosin
light chains, and contractions of human myometrial cells in
labor. It is suggested that mPR at the end of pregnancy
downregulates steroid receptor coactivator-2 (SRC-2), which
in combination with an altered PR-B:PR-A ratio may lead
to decreased transcriptional activation of PR-B [30]. Con-
troversy exists regarding the function of mPRs on cell
membrane, some authors supporting the view that the iso-
formsofthesereceptorsareintracellularandresideprimarily4 Clinical and Developmental Immunology
on the endoplasmic reticulum, while progesterone does not
induce any G protein-dependent signaling of mPRs [31].
2.3. Altered Expression of PR Coregulators. PRs interact with
coregulators that either increase (coactivators) or decrease
(corepressors) their transcriptional activity. These molecules
include among others the CREB-binding protein (CBP) and
the steroid receptor coactivators SRC-1, SRC-2, and SRC-3.
Infundalmyometrialcellsofwomeninlabor,themRNAlev-
els of SRC-2, SRC-3, and CBP are decreased compared to the
nonlabor samples. Nuclear levels of CBP, SRC-2, and SRC-
3 proteins were also reduced in fundal myometrium during
labor. In the mouse uterus in labor, levels of SRC-1, SRC-
3, and CBP were also reduced. The reduced levels of these
coactivators were related to decreased acetylated histone
H3 in both human and mouse, suggesting the closing of
chromatin structure and the reduced expression of PR-
responsivegenesasapossiblemechanismfortheinitiationof
labor [32]. Histone acetylation/deacetylation can also aﬀect
NF-κB activity and proinﬂammatory gene expression (e.g.,
IL-6, IL-8, COX-2, and RANTES), while histone deacetylase
inhibitors exert anti-inﬂammatory eﬀects in myometrium
which may favor uterine quiescence [33].
p54nrb (non-POU-domain-containing, octamer bind-
ing protein) is another molecule that acts as a PR tran-
scriptional corepressor in vitro and which decreases in rat
myometriumattermpregnancies.Itsdecreasedexpressionat
the time of labor may contribute to the increased expression
of labor-associated genes [34].
2.4. Antagonistic Action of NF-κB. An antagonism between
NF-κBandprogesteroneexistsinreproductivetissuesduring
labor. NF-κB belongs to the superclass 4 of transcriptional
factors and is involved in the synthesis of many proinﬂam-
matory mediators such as cytokines and COX-2. Inﬂam-
mation is a critical trigger for the initiation of term and
preterm labor [35], and NF-κB as a transcriptional factor is
implicated in proinﬂammatory stimuli signaling. Proinﬂam-
matory cytokines such as IL-1β and TNF-α,a sw e l la s
lipopolysaccharides (LPSs), can stimulate NF-κBa c t i v i t yi n
the uterus. Additionally, the promoter region of cytokines
g e n e ss u c ha sI L - 1 β, IL-8, and IL-6 contains NF-κBr e c o g -
nition elements, and NF-κB promotes the synthesis of cy-
tokines [36].
NF-κB also stimulates prostaglandin synthesis, regu-
lates matrix metalloproteinase expression, connexin-43 (a
gap junction protein), oxytocin receptor, and may express
inhibitory PR isoforms or increase progesterone metabolism
[18, 36]. In lower segment ﬁbroblasts and in amnion cells
IL-1β induces the synthesis of NF-κB regulated genes,
whileprogesteroneattenuatestheseeﬀects[37].Progesterone
exhibits anti-inﬂammatory properties that maintain uterine
quiescence. MCP-1 is a chemokine which is produced by
decidual, endometrial, myometrial, and trophoblast cells. It
is increased in laboring pregnant myometrium prior to the
onset of labor and attracts leukocytes from the circulation
to the myometrium. MCP-1 is also increased in cultured
myometrial cells in response to IL-1β. Experimentally, in
choriodecidual cells MCP-1 expression is suppressed by
progesterone, while, by contrast, it is stimulated by NF-κB
[38–40].
Antagonism between nuclear factors such as NF-κBa n d
PR for nuclear cofactors is another proposed mechanism
of functional progesterone withdrawal. During labor, the
level of NF-κB changes in the intracellular environment,
and its activity is regulated by interactions with the nuclear
cofactors that increase gene expression, such as CBP/p300.
The antagonism between NF-κB and PR for CBP may
contribute to progesterone withdrawal and expression of
labor-promoting genes [41].
2.5. Progesterone as an Immunomodulator in Pregnancy and
the Antagonism with Cytokines. Progesterone acts as an
immunomodulator that interacts with the immune system
and exerts anti-inﬂammatory eﬀects throughout pregnancy.
Progesteroneinhibitstheactivityofdendriticcells(DCs)that
generate proinﬂammatory responses and favor the induction
of tolerogenic DCs. It also controls the activity of natural
killer (NK) cells and the diﬀerentiation of T cells into T-
helper cell type 2 (Th2) like clones. The Th2 phenotype
induced by progesterone is a prerequisite for the mainte-
nance of pregnancy [42, 43].
Progesterone-induced blocking factor (PIBF) is a protein
which is released from lymphocytes in response to proges-
terone, mediates the immunological eﬀects, and induces the
production of Th2 dominant cytokines like IL-3, IL-4, and
IL-10 [44]. The functional progesterone withdrawal and the
attenuation of progesterone’s eﬀects may contribute, among
other factors, to the swift from a Th2 to a Th1 dominant
eﬀect towards labor. Inﬂammatory response involves Toll-
like receptors, and progesterone modulates the expression of
these receptors in mouse cervix and placenta [45].
Cytokines such as IL-1β and TNF-α increase PGHS-2
and therefore the synthesis of prostaglandins (PG), while
they downregulate prostaglandin 15-hydroxy dehydrogenase
(PGDH), the enzyme that converts PGs into inactive met-
abolites. On the contrary, progesterone promotes PGDH
expression [6]. Progesterone also downregulates prostagl-
andin F2-alpha receptor, which is increased by IL-1β [46].
Via the use of expression microarray and quantitative
reverse transcriptase PCR it has been shown that in human
myometrial cells medroxyprogesterone acetate, a synthetic
progestogen,aﬀectsgenesinvolvedininﬂammatoryresponse
and cytokine activity. Among the downregulated genes of
the study were those of IL-1β, Il-6, Il-11, Il-24, COX-2, and
connexin 43 [47].
Clinically, women with threatened preterm labor have
signiﬁcantly lower serum concentrations of PIBF and IL-10
and signiﬁcant higher serum concentrations of the proin-
ﬂammatory cytokines, IL-6 and interferon-γ (IFN-γ), com-
pared with healthy pregnant women of the control group
[48].
2.6. The Eﬀect of Progesterone Withdrawal on ZEB 1, 2 and
miRNAs. A novel pathway for progesterone withdrawal and
increased expression of contraction-associated genes hasClinical and Developmental Immunology 5
recently been described based on experiments in mice and
human endometrial cells. The levels of micro-RNAs (mi-
RNAs), a class of posttranscriptional regulators that belong
to the mi-RNA-200 family, increase with advanced gestation,
as do the levels of connexin-43 and oxytocin receptor, while
the levels of ZEB1 and ZEB2 (zinc ﬁnger E-box binding
homeobox proteins 1 and 2) repressor transcriptional factor
decline. ZEB1 and ZEB2 inhibit the expression of connexin-
43 and oxytocin receptor and block the oxytocin-induced
contraction of myometrial cells. ZEB1 and ZEB2 also inhibit
the expression of the miRNA-200 family, which in turn
downregulate ZEB1, ZEB2. Progesterone increases the levels
of ZEB1, and thus progesterone withdrawal reverses the
inhibitory eﬀect of ZEB on mi-RNAs. As mi-RNAs increase,
they cause repression of ZEB and thereby promote the syn-
thesis of connexin-43 and oxytocin receptor, thus facilitating
labor [49].
In summary, all the above described mechanisms may
collectively impair progesterone regulation of gene expres-
sion, and this functional progesterone withdrawal promotes
uterine contractility, eﬀecting labor.
2.7. Clinical Applications of Progesterone in Human Labor.
Progesterone has clinical applications with regard to either
the initiation of labor or the arrest of preterm labor. In
women, treatment with antiprogestins induces labor and
delivery, but the most signiﬁcant applications concern
prevention of preterm birth. Numerous studies and meta-
analyses have been conducted to evaluate the eﬃcacy of
progesterone in reducing the incidence and complications of
preterm labor. Progestational agents may reduce the number
of preterm labor and their complications in certain cases,but
the optimal route of administration, the optimal dose, and
thefrequencyofadministrationhavenotbeenclearlydeﬁned
[50–54].
3. Corticotropin-Releasing Hormone Function
on Myometrial Contractility
CRH levels in plasma rise exponentially in human preg-
nancy. However, this increase is more rapid in women who
deliver preterm and slower in women who deliver postterm,
compared to women who deliver at term. This rise begins
early in pregnancy (16–20 weeks) and provides evidence that
placenta acts through CRH as a “clock” that controls the
lengthofpregnancy.Moreover,pretermbirthmaynotbejust
the result of an event around the time of delivery but a
process that begins from early in pregnancy [55].
3.1. Functions of Placental CRH. The rise of CRH is asso-
ciated with a concomitant fall in CRH binding protein
(CRHBP) in late pregnancy. The binding of CRH to CRHBP
makes it biologically inactive and removes it from circula-
tion. The decrease in CRHBP during the ﬁnal three weeks of
pregnancy results in higher concentrations of active CRH in
circulation that contribute to the onset of labor [55, 56]. In
both term and preterm labor, the expression of CRH mRNA
fromtheplacentaisincreased,withthisincreasebeinghigher
in preterm deliveries. However, placental CRHBP mRNA
expression does not change despite the fact that CRHBP
decreases in maternal circulation before labor. This leads to
thehypothesisthatanothersourceofCRHBPexists,suchasa
fetalsourcethatmayberesponsibleforthisdecrease[55,57].
However,despitethefactthatthelevelsofCRHinmater-
nal circulation rise by as much as 1000 times compared to
the nonpregnant state, only a mild hypercortisolism occurs,
mainly due to estrogen-induced production of cortisol-
bindingprotein,andthematernalaxiscontinuesitsfunction.
Thus the functional target of placental CRH is not the
maternal pituitary adrenal axis but the fetal pituitary adrenal
axis[56].PlacentalCRHstimulatesadrenocorticotropichor-
mone (ACTH) production from the fetal pituitary. ACTH
stimulates fetal adrenals to produce dehydroepiandrosterone
(DHEA), dehydroepiandrosterone-sulphate (DHEA-S), and
cortisol. ACTH is also produced in the placenta through
paracrine mechanisms. Placental CRH also exerts a direct
eﬀect by stimulating fetal adrenal zone cells (Figure 2). Fetal
adrenal DHEA is metabolized to estrogens in the placenta
that favor parturition [2, 58, 59]. The produced cortisol
exerts a stimulatory eﬀect on the placenta to further produce
CRH, thus a positive loop is established that causes placental
CRH to rise exponentially as pregnancy advances. Estrogens,
progesterone, and nitric oxide inhibit CRH production,
while a number of neuropeptides exert a stimulatory eﬀect
[2]. Cytokines inﬂuence CRH production. IL-1β and TNF
as well as lipopolysaccharides activate the hypothalamic-
pituitary-adrenal axis and induce CRH production, while
CRH regulates IL-1β, IL-6, and lipopolysaccharides pro-
duction by immune cells [60]. Cytokines also inﬂuence
the metabolism of cortisol. The enzyme 11β-hydroxysteroid
dehydrogenase (11β-HSD) converts cortisol to the inactive
metabolite cortisone. Cytokines such as IL-1β,I L - 6 ,a n d
TNF-αinhibithumanplacenta11β-HSDtype2isoform,and
this could result in increased cortisol levels and therefore
increased CRH production by the placenta [6].
Cortisol produced by fetal adrenals acts on fetal lungs
and produce surfactant protein A (SP-A) that activates
inﬂammatory signals in the uterus, which consequently
enhance myometrial contractility [18]. SP-A signals via Toll-
like receptors. These are membrane-spanning receptors that
act as key regulators in immune system responses [61]. SP-
Ae x e r t si t sa c t i o nv i aa c t i v a t i o no fN F - κB in many cells. In
the mouse, SP-A increases the production of IL-1β and NF-
κB by amniotic ﬂuid macrophages and causes migration of
macrophages in the uterus, resulting in the activation of the
inﬂammatory cascade [62].
CRH may also facilitate the expression of contraction-
associated genes. In myometrial smooth muscle cells from
nonpregnant women, CRH enhances connexin-43 mRNA
and protein expression through nuclear transcription factor
activator protein 1 (AP-1) activation and upregulation
of c-Fos expression, which is an AP-1 subunit. This is
accomplishedinapositiveCRH-dose-dependentmanner.As
a result, in late pregnancy the high levels of CRH possibly
cause an associated increased expression of connexin-43 that
promote myometrial contractions [63]. AP-1 also increases
gene expression in response to many other stimuli, including6 Clinical and Developmental Immunology
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Figure 2: The role of CRH in human labor. CRH is produced in the placenta in response to stimuli that either increase (oxytocin, PG,
stress) or decrease (progesterone) its production. CRH acts on fetal pituitary to increase ACTH production. ACTH and CRH act on fetal
adrenals that produce DHEA-S and cortisol. DHEA-S is metabolized in the placenta to estrogens that increase myometrial contractions
and facilitate labor. Cortisol acts on fetal lungs which produce SP-A, which also increases uterine contractility. Furthermore, placental CRH
acts directly on human myometrial cells via its receptors CRH-R1, -R2, to facilitate the transition from uterine quiescence to myometrial
contractions during labor. CRH: corticotrophin-releasing hormone, PG: prostaglandins, ACTH: adrenocorticotropic hormone, DHEA-S:
dehydroepiandrosterone sulphate, SP-A: surfactant protein A.
cytokines [64]. CRH may also increase the myometrial
response to prostaglandin F2α and therefore modulate the
onset of labor [65].
3.2. The Role of Myometrial CRH Receptor Isoforms in Labor.
CRH exerts its actions through activation of speciﬁc recep-
tors, termed CRH-R1 and CRH-R2. These receptors belong
to the family of seven transmembrane (7TMD) G protein
coupled receptors (GPCRs). CRH receptors are expressed in
several tissues in pregnancy. Both CRH-R1 and CRH-R2 and
their variants have been detected in human myometrium,
anditisbelievedthattheexpressionofvariousisoformsplays
a role in both myometrium quiescence and transition to a
contractile phenotype during labor [66]. Alternative splicing
of CRH-R mRNA results in diﬀerent receptor isoforms (such
as CRH-R1α and CRH-R1d) with diﬀerent activities that
generate a more contractile phenotype [67]. In myometrial
strips from laboring and nonlaboring pregnant women, it
was shown that CRH could inhibit spontaneous contractility
of nonlaboring but not of laboring myometrium, acting via
the CRH-R1 receptor. This eﬀect further implies that CRH
may exhibit a dual role at the myometrium [68].
It is suggested that CRH-R1 promotes relaxation of
smooth muscles via intracellular signals that inhibit phos-
phorylation of the contractile protein myosin light chain
(MLC20). The decreased expression of proteins such as
Gαs-protein (a G protein subunit that activates the cAMP-
dependent pathway by activating adenylate cyclase) towards
the end of pregnancy turns the balance towards myometrial
contractility. The increased expression of CRH-R2 protein
toward onset of labor increases MLC20 phosphorylation and
myometrial contractility [67].
CRH-R1 and CRH-R2 have been identiﬁed both in
the upper and lower uterine segment of laboring and
nonlaboring human myometrium, but during labor CRH-
R1decreasessigniﬁcantlyattheuppersegmentbutnotatthe
lower one. This decreased expression may be related to the
fact that during labor the fundus of the uterus switches to
a highly contractile state, while the lower segment remains
relatively quiescent [69]. Recently a new isoform of CRH-
R has been identiﬁed in human pregnant but not in non-
pregnant myometrium. This isoform is termed CRH-R1β/d
and shows similarities with both CRH-R1β and -R1d, such
as reduced aﬃnity for CRH, negligible signaling, and mainly
cytoplasmic localization. Its expression is maximum at the
earlythirdtrimester,anditisincreasedbyestradiol-17β [70].
3.3. The Eﬀect of Urocortins and Interleukins on CRH Recep-
tors. CRH receptors may also be activated by other agonists
such as the urocortins. Urocortin 2 (UCN 2) is a CRH-R
agonist that is expressed in human pregnant myometrium
and interacts with CRH-R2 receptors and through a sig-
nal transduction pathway involving the protein kinase C
(PKC), the extracellular signal-regulated kinases ERK1/2,
and the RhoA/ROK. Urocortin 2 interaction stimulates
MLC20 phosphorylation, which in turn induces myometrial
contractility [71]. Although urocortins 2 and 3 are expressedClinical and Developmental Immunology 7
in the human placenta, it is not known if they act by
increasingmyometrialcontractilityduringlabor[72].Recent
data have reported that, in human placentas from women
with PPROM and chorioamnionitis, inﬂammatory events
are associated with changes to the CRH-related mechanism
of labor, such as increased CRH, UCN 2, and CRH-R1
mRNA expression and decreased UCN 3 and CRH-R2 ex-
pression [73].
Immune system responses are also associated with
changes to the CRH-related mechanisms of labor. Experi-
ments on both term and preterm, laboring and nonlaboring
humanmyometriumshowthatactivelaborisassociatedwith
increase of CRH-R1α and CRH-R1β mRNA in term and
preterm myometrium. IL-1β induces CRH-R1Tα mRNA and
prostaglandin synthetase 2 (PTGS2) mRNA and protein lev-
els, decreases CRH-R1β mRNA, and impairs CRH-induced
cAMP production. It may therefore be hypothesized that IL-
1β acts as a regulator of CRH-R1 expression and function
that contributes to a preparatory contractile environment
necessary for the initiation of labor [74].
CRH may also act on both term and preterm cervical
ﬁbroblasts and increase IL-8 expression, which is an impor-
tant mediator of cervical ripening [75].
3.4. Clinical Applications of CRH in Human Labor. Several
blood, amniotic ﬂuid, or vaginal ﬂuid markers have been
proposed as predictors of preterm labor, including inter-
leukins, cortisol, ﬁbronectin, ADAM-8, ITAC, estriol, a-FP,
b-HCG, and others [76–81]. Many of these studies have eval-
uatedtheclinicalusefulnessofCRHmeasurementstopredict
preterm labor [56, 82, 83]. Urocortin may also serve as a
biomarker of labor in women with threatened preterm birth
before 34 weeks [84]. However, these observations have
mostly diagnostic and not therapeutic beneﬁt, since no
CRH/CRHreceptor antagonisthasso farbeen identiﬁed that
c a nb eu s e di nh u m a n st op r e v e n tp r e t e r ml a b o r .
4. Interactionsbetween Progesterone
andCRHinLabor
In human placental cells progesterone inhibits CRH pro-
duction, but this eﬀect is modulated diﬀerently from PR-
Aa n dP R - B ,s i n c eP R - Ao v e r e x p r e s s i o nl e a d st od e c r e a s e d
CRH promoter activity, while PR-B increases CRH pro-
moter activity in the presence of exogenous progesterone
[85]. Progesterone induces CRH-R1 and CRH-R1β variants,
which lead to increased action of CRH, eﬀecting under these
conditions uterine quiescence during pregnancy. The eﬀect
of functional progesterone withdrawal on these receptors
mayenablemyometrialcontractionsduring labor[70].CRH
causes relaxation of term and preterm human myometria,
and progesterone acts synergistically to enhance it in term
but not in preterm myometrium. This provides extra
evidencethatprogesteronewithdrawalinlatepregnancymay
lessen the relaxant eﬀect of CRH [86].
CRH may also itself contribute to progesterone with-
drawal towards labor. Experiments in human placental
trophoblasts show that CRH decreases placental production
of progesterone by reducing the levels of the progesterone
synthesis enzymes cytochrome 450 CYP11A1 and HSD3B1.
In contrast, treatment with a CRH antagonist increases pro-
gesterone production. This eﬀect of CRH on progesterone
production is mediated through a PKC-dependent pathway
[87].
5. Conclusion
Progesteroneisahighlyimportant hormonethatcontributes
to the maintenance of pregnancy. Progesterone withdrawal
occurs either by decreasing plasma levels in animals or
by functional withdrawal mechanisms in humans. CRH is
another signiﬁcant hormone which, like progesterone, acts
via diﬀerent mechanisms either to support pregnancy or to
facilitate the process of labor. These two hormones interact
with each other to promote myometrial quiescence or
contractility. Inﬂammatory immune responses such as inﬁl-
tration of uterus with immune cells and production of cy-
tokines contribute signiﬁcantly to the mechanisms of labor.
Progesterone and CRH regulate some of these immune
actions. Despite intensive research for many years, there are
still a large number of enigmas and areas of controversy
regarding human labor and the role of both hormones and
inﬂammation. Animal models do not show similar mecha-
nismstothoseofthehumanfetusandthisisoneoftheobsta-
cles to attaining better understanding of human labor. In
the future, clinical applications based on the actions of
progesterone, CRH and inﬂammatory immune responses
may be essential for the prevention of preterm labor, which
is today a major cause of neonatal morbidity and mortality.
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